SCHEMBL2641015

SCHEMBL2641015

CN(C)C1CCN(N(C)C)C1C1CCN(c2ccc(N)cc2)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.36
GFER P55789 4/20 0.36
KDM4E B2RXH2 3/20 0.36
GAA P10253 3/20 0.36
ALDH1A1 P00352 3/20 0.36
KMT2A Q03164 2/20 0.36
ADRA2C P18825 1/20 0.36
PTK2B Q14289 1/20 0.36
ESR2 Q92731 1/20 0.36
MCHR1 Q99705 3/20 0.34
HTT P42858 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
RAD52 P43351 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
USP2 O75604 1/20 0.33
TP53 P04637 1/20 0.33
POLB P06746 1/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL188111 0.71 MCHR1 (0.48) MAPTGFERKDM4EGAAALDH1A1
SCHEMBL188535 0.71 MCHR1 (0.48) MAPTGFERKDM4EGAAALDH1A1
SCHEMBL188110 0.71 MCHR1 (0.48) MAPTGFERKDM4EGAAALDH1A1
Hydrochloric Acid SCHEMBL5388918 0.70 MCHR1 (0.47) MAPTGFERKDM4EGAAALDH1A1
SCHEMBL2885701 0.70 MAPT (0.38) MAPTGFERKDM4EGAAALDH1A1
SCHEMBL6712762 0.70 MAPT (0.48) MAPTGFERKDM4EGAAALDH1A1
SCHEMBL6606401 0.70 MAPT (0.48) MAPTGFERKDM4EGAAALDH1A1
SCHEMBL6607442 0.70 MAPT (0.48) MAPTGFERKDM4EGAAALDH1A1
SCHEMBL17264101 0.68 MAPT (0.59) MAPTGFERKDM4EGAAALDH1A1
SCHEMBL1409679 0.68 MAPT (0.53) MAPTGFERKDM4EGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968550-B2 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2011-06-28 US disclosed
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-09-06 US disclosed
US-7223788-B2 therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments CYP11B2, CYP11B1, NQO1 MAPT 4800/4885GFER 637/4885KDM4E 2896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.